Last $800.55 MXN
Change Today 0.00 / 0.00%
Volume 0.0
TEVAN On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 4:09 PM 12/2/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Basel Street

Petach Tikva, 49131

Israel

Phone: 972 3 926 7267

Fax: 972 3 923 4050

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes pharmaceuticals in the United States and Europe. Strategy The company’s business strategy seeks to capitalize on the growing global need for medicines, and evolving market, economic and legislative dynamics. The key elements of the company’s strategy include accelerating its growth platforms; extending its global presence; protecting and expanding its core specialty franchises; developing new therapeutic entities; and executing strategic business development transactions. Segments The company’s business includes two primary segments: generic medicines and specialty medicines. Generic Medicines This segment includes chemical and therapeutic equivalents of originator pharmaceuticals in various dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as its active pharmaceutical ingredients (API) business. The company develops, manufactures, and sells generic pharmaceutical products in various dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. It offers a range of basic chemical entities, as well as specialized product families such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. The company produces approximately 300 APIs for its own use and for sale to third parties in many therapeutic areas. The company utilizes various production technologies, including chemical synthesis, semi-synthetic fermentation, enzymatic synthesis, high potency manufacturing, plant extract technology and peptides synthesis. The company’s technology and expertise in the field of solid state particle technology enable it to meet specifications for particle size distribution, bulk density, specific surface area, polymorphism, as well as other characteristics. United States: The company operates as a generic drug company in the United States. It markets approximately 375 generic products in approximately 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. Marketing and Sales: In the United States, the company’s wholesale and retail selling efforts are supported by advertising in professional journals and pharmacy Websites, as well as participating in key medical and pharmaceutical conferences. Europe: The company operates as a generic pharmaceutical company in Europe. The company has a product portfolio of approximately 450 molecules. In France, the company has a portfolio of approximately 300 molecules. In the United Kingdom, the company operates as a supplier to the National Health Service. The company has a portfolio of approximately 315 molecules. In Italy, the company has a generic portfolio of approximately 220 molecules. In Spain, its generic product portfolio has approximately 210 molecules. Rest of the World Markets (ROW) The company’s ROW markets include all countries other than the United States and those included under Europe. Its key ROW markets are Japan, Russia, Latin America, Canada and Israel. The countries in this category range from highly regulated, pure generic markets such as Canada, to hybrid markets such as Japan and Brazil, to branded generics markets such as certain Commonwealth of Independent States markets and Latin American markets. Japan In 2012, the company integrated its generic operations into a single entity, Teva Seiyaku (Teva Pharma Japan, Inc.), which includes production and R&D capabilities, as well as a strong sales and marketing team. Russia In Russia, the company markets a portfolio of branded generic products, as well as over the counter (OTC) pharmaceutical products and specialty products. The company has a portfolio of approximately 130 products sold to both retail and hospital channels. Latin America The company markets a portfolio of generic medicines in most Latin American countries. Its products are generally manufactured in its facilities in Mexico, Chile, Argentina and Peru. The company has a presence in most of the m

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $800.55 MXN 0.00

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TEVAN.
View Industry Companies
 

Industry Analysis

TEVAN

Industry Average

Valuation TEVAN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.